K7M3 / K7M3-luc Orthotopic Mouse Model Service for Sarcoma

The K7M3 / K7M3-luc orthotopic mouse model delivers one of the most aggressive syngeneic osteosarcoma systems available, implanting a lung-metastasis-selected murine line into the tibial marrow cavity of immunocompetent BALB/c mice where it drives rapid bone destruction and pulmonary spread. Alfa Cytology provides this model as a fully managed preclinical service — authenticated cell banking, precision intratibial surgery with X-ray and bioluminescence monitoring, dosed intervention including NK-cell, cytokine, and bisphosphonate strategies, and complete terminal pathology — giving sponsors a demanding bone-sarcoma platform without standing up specialized surgical and imaging capabilities internally.

Overview of K7M3 / K7M3-luc Orthotopic Mouse Model for Sarcoma

K7M3 belongs to the celebrated K7 family of murine osteosarcoma lines, all tracing back to a tumor that arose spontaneously in the femur of a BALB/c mouse nearly 900 days of age. Whereas its parent K7M2 was selected through repeated cycles of intraosseous implantation and lung-metastasis harvest, K7M3 was taken further: after intravenous challenge of the parental line, the lung metastases that escaped the pulmonary first-pass defense were recovered and expanded, locking in a phenotype of exceptional metastatic aggression. In orthotopic comparisons, K7M3 outruns its relatives — among the clonally related K7M2, K12, and K7M3 lines, K7M3 is classified as the highly aggressive member, with K7M2 and K12 substantially milder. Its aggression is molecularly legible: the line expresses RANKL (unlike the milder K12), secretes abundant osteoprotegerin, and actively drives osteoclast differentiation and bone resorption, making it the natural substrate for studying osteosarcoma-mediated osteolysis and the bone-tumor vicious cycle; bisphosphonates have been shown to blunt K7M3-driven osteolysis by attenuating tumor MCP-1 and RANKL expression.

Fig 1. Syngeneic orthotopic K7M3 model: BLI of primary bone tumor with concurrent spontaneous pulmonary metastases (A), histology of lung metastatic lesions (B), μCT showing profound osteolysis of the primary lesion with unaffected contralateral tibia (C), and macroscopic tumor burdens (E). (Fan, Timothy M., et al., 2020)

A second distinctive thread is immune evasion. Work on the K7 family demonstrated that Fas-positive osteosarcoma cells are efficiently cleared from the lung within about 48 hours of intravenous arrival, while K7M3 cells — selected precisely for surviving that gauntlet — are characteristically Fas-negative or Fas-low, a corruption of the Fas pathway that delays pulmonary clearance and boosts metastatic potential; this same mechanism has been shown to blunt the efficacy of inhaled chemotherapeutics such as aerosol gemcitabine. The model has consequently become a preferred arena for pulmonary-delivery and innate-immunity strategies, hosting studies of aerosol interleukin-2, natural killer cell therapy, β-glucan plus CD40-agonist combinations, and therapeutic vaccination with tumor-lysate-loaded dendritic cells. Orthotopically, K7M3 is implanted by intratibial injection of a compact inoculum — published protocols use two 10 μL injections of 1 × 10⁵ cells given 24 hours apart — with weekly X-ray or caliper assessment, amputation at a defined tumor threshold, and histological scoring of femoral relapse and lung metastases at termination. The K7M3-luc derivative, engineered with firefly luciferase, adds quantitative whole-body tracking of primary and pulmonary tumor burden, sharpening response kinetics for every one of these study styles.

Cell Line Information: K7M3 / K7M3-luc

K7M3 (Cellosaurus CVCL_XG68; available from Hysigen as TCM-C791) is a murine osteosarcoma subline of K7M2, established by intravenous injection of the parent line into mice followed by harvest of the resulting lung metastases, as reported by Gordon and colleagues in 2007. The luciferase-tagged K7M3-luc derivative was originally generated at the NCI and is widely distributed through the osteosarcoma research community for optical tracking studies. Principal characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the K7M3 / K7M3-luc orthotopic osteosarcoma model places the entire study under one accountable roof: authenticated, low-passage cell banks are expanded and luciferase-verified, syngeneic BALB/c hosts are prepared and acclimated, the compact intratibial inoculum is delivered by microsurgeons experienced with marrow-cavity technique, primary osteolysis is followed by scheduled X-ray and bioluminescence imaging, and your treatment arms — from bisphosphonates and inhaled agents to NK-cell therapies and vaccine combinations — run through amputation, terminal lung histology, and relapse scoring under IACUC-compliant conditions, with results returned as an audit-ready data package.

Workflow of K7M3 / K7M3-luc Orthotopic Mouse Model Construction

Orthotopic K7M3 work rewards discipline in three places: compact-inoculum tibial surgery, radiographic plus optical monitoring, and rigorous metastatic histopathology. A standard program unfolds as follows.

1. Cell preparation and quality control: K7M3 or K7M3-luc cells are expanded at low passage, confirmed mycoplasma-free, and luciferase activity is validated in vitro; the working inoculum is prepared at 1 × 10⁵ cells in 10 μL PBS per injection shortly before surgery.
2. Host selection and acclimation: Male or female BALB/c mice, typically 6–8 weeks of age, are quarantined and acclimated in a specific-pathogen-free barrier facility prior to the procedure.
3. Anesthesia and tibial access: Under isoflurane anesthesia, the proximal tibia is exposed through a small incision, the knee is flexed, and a 27-gauge needle is advanced through the tibial plateau into the marrow cavity.
4. Intratibial inoculation: The 10 μL cell suspension is injected slowly into the marrow cavity; the procedure is repeated 24 hours later into the same limb, a two-hit inoculation format reported in published K7M3 protocols to standardize take rates.
5. Closure and postoperative care: The skin is closed, analgesia is administered, and mice are monitored daily for weight, gait, and wound integrity, with humane endpoints defined in advance.
6. Primary tumor monitoring: Tibial tumors are assessed weekly by caliper measurement and X-ray radiography, which captures the osteolytic signature of K7M3 growth; luciferase-tagged cohorts additionally undergo scheduled bioluminescence imaging after intraperitoneal D-luciferin injection.
7. Randomization, treatment, and amputation: Mice are randomized into treatment arms at a defined tumor volume, test articles are dosed according to protocol, and the affected limb is amputated once the primary tumor reaches the preset threshold (for example ~1.5 cm³), so that anti-metastatic efficacy is measured against established pulmonary disease.
8. Endpoint analysis and reporting: At termination, femora are examined histologically for local relapse and lungs for metastatic burden, with necrotic versus viable tumor areas scored per published criteria; imaging signals are reconciled with histology, and all data are consolidated into the final report.

Fig 2. K7M3 / K7M3-luc orthotopic mouse model construction workflow.

Case Study-K7M3 / K7M3-luc Orthotopic Mouse Model Development

Alfa Cytology has applied the K7M3 / K7M3-luc orthotopic platform to preclinical programs spanning osteolysis-focused interventions, bisphosphonate evaluation, pulmonary-delivery strategies, and innate-immunity combinations in osteosarcoma. In these engagements, radiographic and bioluminescence readouts tracked the osteolytic primary tumor and pulmonary metastatic burden in individual animals, while terminal histology quantified femoral relapse and lung metastases against predefined scoring criteria. Study parameters — inoculum format, imaging cadence, amputation thresholds, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

K7M3 studies are won or lost on surgical consistency, radiographic discipline, and metastasis-pathology rigor. Alfa Cytology fields all three capabilities in-house, making the K7M3 / K7M3-luc orthotopic model a dependable instrument for aggressive sarcoma research.

• Proven dual-injection intratibial technique, standardized for reproducible take rates.
• Combined X-ray and bioluminescence monitoring, capturing both the osteolytic and whole-body dimensions of disease.
• The most aggressive K7-family phenotype, with documented RANKL-driven osteolysis biology.
• Established amputation-based anti-metastatic designs, mirroring the clinical adjuvant setting.
• Expertise in pulmonary-delivery and innate-immunity study styles, including aerosol agents, NK cells, and vaccine combinations.
• Predefined, publication-grade histological scoring criteria for femoral relapse and lung metastasis burden.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your sarcoma program requires an aggressive, osteolysis-competent orthotopic platform, contact us today to discuss K7M3 / K7M3-luc study design, imaging strategy, and endpoint scoring with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology is ready to move your preclinical study forward.

For research use only. Not intended for any clinical use.